The FDA user fee law may end up serving as a catalyst not only for the development of new antibiotics, but also for the agency’s revamping of its drug approval processes for anti-infective drugs.
A mix of new incentives specifically geared for antibiotics, such as additional marketing exclusivity and guidance on streamlining the drug...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?